Vimpat (lacosamide)
- Region
- 🇪🇺 EU
- Active substance
- lacosamide
- Company
- UCB Pharma SA
- Status
- Authorised
- Therapeutic area
- Epilepsy
- CHMP opinion
- Thu 26 Jun 2008
- EU approval
- Fri 29 Aug 2008
- Application
- EMEA/H/C/000863
- ATC
- N03AX18
- Official record
- www.ema.europa.eu
Indication
Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Lacosamide Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Lacosamide UCB Authorised · UCB Pharma S.A.
- 🇪🇺 Lacosamide Adroiq Authorised · Extrovis EU Ltd
- 🇪🇺 Lacosamide Pain UCB Pharma Application withdrawn · UCB Pharma S.A.
Follow Vimpat
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.